Abstract
Background
Medullary thyroid carcinoma (MTC) is a rare development of thyroid cancer with a no negligible mortality rate. Our aim was to determine factors that predict outcome in patients with MTC.
Methods
We reviewed the records of all patients with MTC (n=56) who underwent treatment at our institution between January 1990 and December 2000. Univariate and multivariate analysis of clinicopathologic predictors of MTC outcome were performed to identify subsets of patients with different probabilities in terms of overall survival, local recurrence, and distant metastases.
Results
Multivariate analysis demonstrated that a statistically significant decrease in overall survival is associated with T4b tumours (p=0.06), the presence of distant metastases at the time of presentation (p=0.033), lymphatic invasion (p=0.099), and postoperative treatment (p=0.045).
Conclusions
The analysis of survival curves of patients with MTC shows that the occurrence of locoregional and distant metastases occurs preferentially within the first 5 years, which identifies this as a crucial period for follow-up. In this series of patients with MTC, the tumours classified as T4b, metastases at presentation, the presence of lymphovascular invasion, and postoperative treatment were the most important prognostic features. At present, there is no available beneficial adjuvant therapy. However, as the development of molecular therapy progresses, it should be tested in clinical trials with the purpose of achievement of novel targeted therapies for selected MTC patients with risk factors.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Donahower GF, Schumacher OP, Hazard JB. Medullary carcinoma of the thyroid-a cause of Cushing's syndrome: report of two cases. J Clin Endocrinol Metab. 1968; 28:1199–204
Williams ED. Histogenesis of medullary carcinoma of the thyroid. J Clin Pathol. 1966;19:114–8.
Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma: a population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program, 1975–1991. Cancer. 1997;79:564–73.
Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A national cancer database report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer. 1998;85:2658–48.
Ukkat J, Gimm O, Brauckhoff M, Bilkenroth U, Dralle H. Single center experience in primary surgery for medullary thyroid carcinoma. World J Surg. 2004;28:1271–4.
Bugalho MJ, Frade JP, Santos JR, Limbert E, Sobrinho L. Molecular analysis of the RET proto-oncogene in patients with sporadic medullary thyroid carcinoma: a novel point mutation in the extracellular cysteine-rich domain. Eur J Endocrinol. 1997;136:423–6.
Scurini C, Quadro L, Fattoruso O, et al. Germline and somatic mutations of the RET proto-oncogene in apparently sporadic medullary thyroid carcinomas. Mol Cell Endocrinol. 1998;137:51–7.
Donnis-Keller H, Dou S, Chi D, et al. Mutations of the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 1993;2:851–6.
Mulligan LM, Kwok JB, Healey CS, et al. Germline mutations of the RET protooncogene in multiple endocrine neoplasia 2A. Nature. 1993;363:458–60.
Steiner AL, Goodman AD, Powers SR. Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and cushing's disease: multiple endocrine neoplasia, type 2. Medicine. 1968;47:371–409.
Phay JE, Moley JF, Lairmore TC. Multiple endocrine neoplasias. Semin Surg Oncol. 2000;18:324–32.
Alsanea O, Clark O. Familial thyroid cancer. Curr Opin Oncol. 2001;13:44–51.
Wolfe HJ, Melvin KEW, Cervi-Skinner SJ, et al. C-cell hyperplasia preceding medullary thyroid carcinoma. N Engl J Med. 1975;289:457–41.
Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumours. J Clin Oncol. 2002;20:3898–905.
Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol. 2004;11:465–75.
Ponder BAJ, Finer N, Coffey R, et al. Family screening in medullary thyroid carcinoma patients presenting without a family history. Oncol J Med. 1988;63:319–42.
Mirallié E, Iacobone M, Sebag F, Henry JF. Results of surgical treatment of sporadic medullary thyroid carcinoma following routine measurement of serum calcitonin. Eur J Surg Oncol. 2004;30:790–5.
Kebebew E, Ituarte P, Siperstein A, Duh QY, Clark O. Medullary thyroid carcinoma. Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139–48.
Tisell LE, Hansson G, Jansson S, et al. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery. 1986;99:60–6.
Gimm O, Ukkat J, Dralle H. Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J Surg. 1998;22:562–7.
van Heerden JA, Grant CS, Gharib H, et al. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg. 1990;212:395–400.
Saad MF, Ordonez NG, Rashid RK, et al. Medullary carcinoma of the thyroid: a study of the clinical features and prognostic factors in 161 patients. Medicine. 1984; 63:319–42.
Bergholm U, Adami HO, Bergstrom R, et al. Clinical characteristics in sporadic and familial medullary thyroid carcinoma: a nationwide study of 249 patients in Sweden from 1959 through 1981. Cancer. 1989;63:1196–204.
Raue F, Kotzerke J, Reinwein D, Schroder S, Roher HD, Deckart H. Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. Clin Invest. 1993;71:7–12.
Brierley JD, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid. 1996;6:305–10.
Evans DB, Fleming JB, Lee JE, et al. The surgical treatment of medullary thyroid carcinoma. Semin Surg Oncol. 1999;16:50–63.
Vitale G, Caraglia M, Ciccarelli A, Lupoli G, Abbruzzese A. Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer. 2001;91:1797–808.
Treseler PA, Clark OH. Prognostic factors in thyroid carcinoma. Surg Oncol Clin North Am. 1997;6:555–98.
Dottorini ME, Assi A, Sironi M, et al. Multivariate analysis of patients with medullary thyroid carcinoma: prognostic significance and impact on treatment of clinical and pathologic variables. Cancer. 1996;77:1556–65.
Chong GC, Beahrs OH, Sizemore GW, et al. Medullary carcinoma of the thyroid gland. Cancer. 1975:55:695–704.
Hyer SL, Vini L, A'Hern R, Harmer C. Medullary thyroid Cancer: multivariate analysis of prognostic factors influencing survival. Eur J Surg Oncol. 2000;26:686–90.
Gharib H, McConahey WM, Tiegs RD, Bergstralh EJ, Goeliner JR, Grant CS. Medullary thyroid carcinoma: clinicopathologic features and long-term followup of 65 patients treated during 1946 through 1970. Mayo Clin Proc. 1992;67:934–9.40.
Rougier P, Parmentier C, Laplanche A, Lefevre M, Travagli JP, Caillou B. Medullary thryoid carcinoma: prognostic factors and treatment. Int J Radiat Oncol Biol Phys. 1983;9:161–9.
Tennvall J, Bjorklund A, Moller T, Ranstam J, Akerman M. Prognostic factors of papillary, follicular and medullary carcinomas of the thyroid gland: Retrospective multivariate analysis of 216 patients with a median follow-up of 11 years. Acta Radiol Oncol. 1985;24:17–24.
Schroder S, Bocker W, Baisch H, et al. Prognostic factors in medullary thyroid carcinomas: survival in relation to age, sex, stage, histology, immunocytochemistry and DNA content. Cancer. 1988;61:806–16.
Chambers AF, Naumov GN, Varghese HJ, et al. Critical steps in hematogenous metastases-an overview. Surg Oncol Clin North Am. 2001;10:243–55.
Moley JF. Medullary thyroid cancer. Surg Clin North Am. 1995;75:405–20.
Pelizzo MR, Bernante P, Piotto A, Toniato A, Girelli ME, Busnardo B. The extent for surgery for thyroid medullary cancer. Tumori. 1994;80:427–32.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Callejo, I.P., Brito, J.A., Zagalo, C.M. et al. Medullary thyroid carcinoma: multivariate analysis of prognostic factors influencing survival. Clin Transl Oncol 8, 435–443 (2006). https://doi.org/10.1007/s12094-006-0198-2
Issue Date:
DOI: https://doi.org/10.1007/s12094-006-0198-2